The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Rabies Immune Globulin (Human) Market Research Report 2024
Synopsis
Global Rabies Immune Globulin (Human) market is projected to reach US$ 1973.9 million in 2029, increasing from US$ 1500 million in 2022, with the CAGR of 4.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rabies Immune Globulin (Human) market research.
The market for Rabies Immune Globulin (Human) is primarily driven by the incidence of rabies in different regions of the world. According to the World Health Organization, rabies is present in more than 150 countries, with an estimated 59,000 human deaths annually. The majority of these deaths occur in Asia and Africa, where access to post-exposure prophylaxis may be limited.
In addition, the market for Rabies Immune Globulin (Human) is also influenced by government policies and regulations related to rabies prevention and control. Many countries have established national vaccination programs and guidelines for post-exposure prophylaxis, which may include the use of Rabies Immune Globulin (Human).
Overall, the market for Rabies Immune Globulin (Human) is expected to continue to grow as awareness of rabies and the importance of post-exposure prophylaxis increases, particularly in regions with high incidence of the disease.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Rabies Immune Globulin (Human) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Sanofi
Kamada
Bharat Serum
Bio Products Laboratory
Shanghai RAAS
Weiguang Bio
Shuanglin Bio
CBPO
CNBG
Sichuan Yuanda Shuyang
Kedrion Biopharma
Congruent Pharmachem
hualanbio
Segment by Type
HyperRAB S/D
KEDRAB
Segment by Application
Clinic
Hospital
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rabies Immune Globulin (Human) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Global Rabies Immune Globulin (Human) market is projected to reach US$ 1973.9 million in 2029, increasing from US$ 1500 million in 2022, with the CAGR of 4.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rabies Immune Globulin (Human) market research.
The market for Rabies Immune Globulin (Human) is primarily driven by the incidence of rabies in different regions of the world. According to the World Health Organization, rabies is present in more than 150 countries, with an estimated 59,000 human deaths annually. The majority of these deaths occur in Asia and Africa, where access to post-exposure prophylaxis may be limited.
In addition, the market for Rabies Immune Globulin (Human) is also influenced by government policies and regulations related to rabies prevention and control. Many countries have established national vaccination programs and guidelines for post-exposure prophylaxis, which may include the use of Rabies Immune Globulin (Human).
Overall, the market for Rabies Immune Globulin (Human) is expected to continue to grow as awareness of rabies and the importance of post-exposure prophylaxis increases, particularly in regions with high incidence of the disease.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Rabies Immune Globulin (Human) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Sanofi
Kamada
Bharat Serum
Bio Products Laboratory
Shanghai RAAS
Weiguang Bio
Shuanglin Bio
CBPO
CNBG
Sichuan Yuanda Shuyang
Kedrion Biopharma
Congruent Pharmachem
hualanbio
Segment by Type
HyperRAB S/D
KEDRAB
Segment by Application
Clinic
Hospital
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rabies Immune Globulin (Human) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Rabies Immune Globulin (Human) Market Overview
1.1 Product Overview and Scope of Rabies Immune Globulin (Human)
1.2 Rabies Immune Globulin (Human) Segment by Type
1.2.1 Global Rabies Immune Globulin (Human) Market Value Comparison by Type (2023-2029)
1.2.2 HyperRAB S/D
1.2.3 KEDRAB
1.3 Rabies Immune Globulin (Human) Segment by Application
1.3.1 Global Rabies Immune Globulin (Human) Market Value by Application: (2023-2029)
1.3.2 Clinic
1.3.3 Hospital
1.4 Global Rabies Immune Globulin (Human) Market Size Estimates and Forecasts
1.4.1 Global Rabies Immune Globulin (Human) Revenue 2018-2029
1.4.2 Global Rabies Immune Globulin (Human) Sales 2018-2029
1.4.3 Global Rabies Immune Globulin (Human) Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Rabies Immune Globulin (Human) Market Competition by Manufacturers
2.1 Global Rabies Immune Globulin (Human) Sales Market Share by Manufacturers (2018-2023)
2.2 Global Rabies Immune Globulin (Human) Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Rabies Immune Globulin (Human) Average Price by Manufacturers (2018-2023)
2.4 Global Rabies Immune Globulin (Human) Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Rabies Immune Globulin (Human), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Rabies Immune Globulin (Human), Product Type & Application
2.7 Rabies Immune Globulin (Human) Market Competitive Situation and Trends
2.7.1 Rabies Immune Globulin (Human) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Rabies Immune Globulin (Human) Players Market Share by Revenue
2.7.3 Global Rabies Immune Globulin (Human) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Rabies Immune Globulin (Human) Retrospective Market Scenario by Region
3.1 Global Rabies Immune Globulin (Human) Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Rabies Immune Globulin (Human) Global Rabies Immune Globulin (Human) Sales by Region: 2018-2029
3.2.1 Global Rabies Immune Globulin (Human) Sales by Region: 2018-2023
3.2.2 Global Rabies Immune Globulin (Human) Sales by Region: 2024-2029
3.3 Global Rabies Immune Globulin (Human) Global Rabies Immune Globulin (Human) Revenue by Region: 2018-2029
3.3.1 Global Rabies Immune Globulin (Human) Revenue by Region: 2018-2023
3.3.2 Global Rabies Immune Globulin (Human) Revenue by Region: 2024-2029
3.4 North America Rabies Immune Globulin (Human) Market Facts & Figures by Country
3.4.1 North America Rabies Immune Globulin (Human) Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Rabies Immune Globulin (Human) Sales by Country (2018-2029)
3.4.3 North America Rabies Immune Globulin (Human) Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Rabies Immune Globulin (Human) Market Facts & Figures by Country
3.5.1 Europe Rabies Immune Globulin (Human) Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Rabies Immune Globulin (Human) Sales by Country (2018-2029)
3.5.3 Europe Rabies Immune Globulin (Human) Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Rabies Immune Globulin (Human) Market Facts & Figures by Country
3.6.1 Asia Pacific Rabies Immune Globulin (Human) Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Rabies Immune Globulin (Human) Sales by Country (2018-2029)
3.6.3 Asia Pacific Rabies Immune Globulin (Human) Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Rabies Immune Globulin (Human) Market Facts & Figures by Country
3.7.1 Latin America Rabies Immune Globulin (Human) Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Rabies Immune Globulin (Human) Sales by Country (2018-2029)
3.7.3 Latin America Rabies Immune Globulin (Human) Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Rabies Immune Globulin (Human) Market Facts & Figures by Country
3.8.1 Middle East and Africa Rabies Immune Globulin (Human) Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Rabies Immune Globulin (Human) Sales by Country (2018-2029)
3.8.3 Middle East and Africa Rabies Immune Globulin (Human) Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Rabies Immune Globulin (Human) Sales by Type (2018-2029)
4.1.1 Global Rabies Immune Globulin (Human) Sales by Type (2018-2023)
4.1.2 Global Rabies Immune Globulin (Human) Sales by Type (2024-2029)
4.1.3 Global Rabies Immune Globulin (Human) Sales Market Share by Type (2018-2029)
4.2 Global Rabies Immune Globulin (Human) Revenue by Type (2018-2029)
4.2.1 Global Rabies Immune Globulin (Human) Revenue by Type (2018-2023)
4.2.2 Global Rabies Immune Globulin (Human) Revenue by Type (2024-2029)
4.2.3 Global Rabies Immune Globulin (Human) Revenue Market Share by Type (2018-2029)
4.3 Global Rabies Immune Globulin (Human) Price by Type (2018-2029)
5 Segment by Application
5.1 Global Rabies Immune Globulin (Human) Sales by Application (2018-2029)
5.1.1 Global Rabies Immune Globulin (Human) Sales by Application (2018-2023)
5.1.2 Global Rabies Immune Globulin (Human) Sales by Application (2024-2029)
5.1.3 Global Rabies Immune Globulin (Human) Sales Market Share by Application (2018-2029)
5.2 Global Rabies Immune Globulin (Human) Revenue by Application (2018-2029)
5.2.1 Global Rabies Immune Globulin (Human) Revenue by Application (2018-2023)
5.2.2 Global Rabies Immune Globulin (Human) Revenue by Application (2024-2029)
5.2.3 Global Rabies Immune Globulin (Human) Revenue Market Share by Application (2018-2029)
5.3 Global Rabies Immune Globulin (Human) Price by Application (2018-2029)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.1.4 CSL Behring Rabies Immune Globulin (Human) Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Grifols Rabies Immune Globulin (Human) Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Rabies Immune Globulin (Human) Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Kamada
6.4.1 Kamada Corporation Information
6.4.2 Kamada Description and Business Overview
6.4.3 Kamada Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kamada Rabies Immune Globulin (Human) Product Portfolio
6.4.5 Kamada Recent Developments/Updates
6.5 Bharat Serum
6.5.1 Bharat Serum Corporation Information
6.5.2 Bharat Serum Description and Business Overview
6.5.3 Bharat Serum Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bharat Serum Rabies Immune Globulin (Human) Product Portfolio
6.5.5 Bharat Serum Recent Developments/Updates
6.6 Bio Products Laboratory
6.6.1 Bio Products Laboratory Corporation Information
6.6.2 Bio Products Laboratory Description and Business Overview
6.6.3 Bio Products Laboratory Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bio Products Laboratory Rabies Immune Globulin (Human) Product Portfolio
6.6.5 Bio Products Laboratory Recent Developments/Updates
6.7 Shanghai RAAS
6.6.1 Shanghai RAAS Corporation Information
6.6.2 Shanghai RAAS Description and Business Overview
6.6.3 Shanghai RAAS Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Shanghai RAAS Rabies Immune Globulin (Human) Product Portfolio
6.7.5 Shanghai RAAS Recent Developments/Updates
6.8 Weiguang Bio
6.8.1 Weiguang Bio Corporation Information
6.8.2 Weiguang Bio Description and Business Overview
6.8.3 Weiguang Bio Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Weiguang Bio Rabies Immune Globulin (Human) Product Portfolio
6.8.5 Weiguang Bio Recent Developments/Updates
6.9 Shuanglin Bio
6.9.1 Shuanglin Bio Corporation Information
6.9.2 Shuanglin Bio Description and Business Overview
6.9.3 Shuanglin Bio Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Shuanglin Bio Rabies Immune Globulin (Human) Product Portfolio
6.9.5 Shuanglin Bio Recent Developments/Updates
6.10 CBPO
6.10.1 CBPO Corporation Information
6.10.2 CBPO Description and Business Overview
6.10.3 CBPO Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.10.4 CBPO Rabies Immune Globulin (Human) Product Portfolio
6.10.5 CBPO Recent Developments/Updates
6.11 CNBG
6.11.1 CNBG Corporation Information
6.11.2 CNBG Rabies Immune Globulin (Human) Description and Business Overview
6.11.3 CNBG Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.11.4 CNBG Rabies Immune Globulin (Human) Product Portfolio
6.11.5 CNBG Recent Developments/Updates
6.12 Sichuan Yuanda Shuyang
6.12.1 Sichuan Yuanda Shuyang Corporation Information
6.12.2 Sichuan Yuanda Shuyang Rabies Immune Globulin (Human) Description and Business Overview
6.12.3 Sichuan Yuanda Shuyang Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Sichuan Yuanda Shuyang Rabies Immune Globulin (Human) Product Portfolio
6.12.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.13 Kedrion Biopharma
6.13.1 Kedrion Biopharma Corporation Information
6.13.2 Kedrion Biopharma Rabies Immune Globulin (Human) Description and Business Overview
6.13.3 Kedrion Biopharma Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Kedrion Biopharma Rabies Immune Globulin (Human) Product Portfolio
6.13.5 Kedrion Biopharma Recent Developments/Updates
6.14 Congruent Pharmachem
6.14.1 Congruent Pharmachem Corporation Information
6.14.2 Congruent Pharmachem Rabies Immune Globulin (Human) Description and Business Overview
6.14.3 Congruent Pharmachem Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Congruent Pharmachem Rabies Immune Globulin (Human) Product Portfolio
6.14.5 Congruent Pharmachem Recent Developments/Updates
6.15 hualanbio
6.15.1 hualanbio Corporation Information
6.15.2 hualanbio Rabies Immune Globulin (Human) Description and Business Overview
6.15.3 hualanbio Rabies Immune Globulin (Human) Sales, Revenue and Gross Margin (2018-2023)
6.15.4 hualanbio Rabies Immune Globulin (Human) Product Portfolio
6.15.5 hualanbio Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Rabies Immune Globulin (Human) Industry Chain Analysis
7.2 Rabies Immune Globulin (Human) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Rabies Immune Globulin (Human) Production Mode & Process
7.4 Rabies Immune Globulin (Human) Sales and Marketing
7.4.1 Rabies Immune Globulin (Human) Sales Channels
7.4.2 Rabies Immune Globulin (Human) Distributors
7.5 Rabies Immune Globulin (Human) Customers
8 Rabies Immune Globulin (Human) Market Dynamics
8.1 Rabies Immune Globulin (Human) Industry Trends
8.2 Rabies Immune Globulin (Human) Market Drivers
8.3 Rabies Immune Globulin (Human) Market Challenges
8.4 Rabies Immune Globulin (Human) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
